Does Growth Hormone Treatment Influence Pubertal Development in Short Children?

Aim: To study the influence of growth hormone (GH) treatment on the initiation and progression of puberty in short children. Methods: This prospective, randomized, controlled study included 124 short children (33 girls) who received GH treatment (Genotropin (R); Pfizer Inc.) from a mean age of 11 years until near adult height [intent-to-treat (ITT) population]. Children were randomized into three groups: controls (n = 33), GH 33 mu g/kg/day (n = 34) or GH 67 mu g/kg/day (n = 57). Prepubertal children at study start constituted the per-protocol (PP) population (n = 101). Auxological measurements were made and puberty was staged every 3 months. Serum sex-steroid concentrations were assessed every 6 months. Results: No significant differences were found between the groups, of both PP and ITT populations, in time elapsed from start of treatment until either onset of puberty, age at start of puberty or age at final pubertal maturation in either sex. In the ITT population, pubertal duration was significantly longer in GH-treated girls, and maximum mean testicular volume was significantly greater in GH-treated boys than controls, but there were no differences in testosterone levels between the groups. Conclusion: GH treatment did not influence age at onset of puberty and did not accelerate pubertal development. In boys, GH treatment appeared to increase testicular volume. Copyright (C) 2011 S. Karger AG, Basel